A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function
Status:
Completed
Trial end date:
2018-03-31
Target enrollment:
Participant gender:
Summary
Study AG120-C-012 is a Phase 1, open-label, single-dose study designed to evaluate the PK,
safety, and tolerability of a single 500 mg AG-120 (Ivosidenib) dose in subjects with mild or
moderate hepatic impairment (HI) compared to subjects with normal hepatic function. The study
will be conducted at 2 US centers.